FDA DTC Study Should Use Real Ads, Be More Conversational – AstraZeneca
Executive Summary
AstraZeneca is asking FDA to incorporate a more qualitative approach in the initial phase of its planned evaluation of the "brief summary" section of direct-to-consumer print advertising
You may also be interested in...
Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study
FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension
Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study
FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension
DTC Risk Disclosures Examined By FDA; Do Minor Risks Swamp Major Ones?
FDA will evaluate how the presence of minor safety risks in the brief summary of print direct-to-consumer advertisements impacts consumer comprehension of major risks